These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Synthesis, physicochemical and anticonvulsant properties of new N-[(4-arylpiperazin-1-yl)alkyl]-3-phenyl- and 3-(3-methyl-phenyl)-pyrrolidine-2,5-diones.
    Author: Obniska J, Chlebek I, Pichór J, Kopytko M, Kamiński K.
    Journal: Acta Pol Pharm; 2009; 66(6):639-47. PubMed ID: 20050528.
    Abstract:
    The series of N-[(4-arylpiperazin-1-yl)-alkyl]-3-phenyl- and 3-(3-methylphenyl)-pyrrolidine-2,5-diones [VIII-XXV] were synthesized and evaluated for anticonvulsant and neurotoxic properties. Initial anticonvulsant screening was performed in mice, using intraperitoneal (ip) maximal electroshock-induced seizures (MES) and subcutaneous pentylenetetrazole-induced (scPTZ) seizure threshold tests. The neurotoxicity was determined applying the rotorod screen. Compounds VIII-XXV revealed protection only in the electrically induced seizures or were inactive. The most active were Mannich bases of 3-(3-methylphenyl)-pyrrolidine-2,5-dione with electron-withdrawing substituents at position-3 of 4-arylpiperazine fragment [XVII, XVIII], as well as compounds with ethylene or propylene spacer between imide and 4-arylpiperazine nitrogen atoms [XX-XXII, XXV]. All these compounds showed anti-MES protection in mice at doses of 100 mg/kg. Additionally, when given orally, compound XVIII was also active in rats MES screen at a dose of 30 mg/kg.
    [Abstract] [Full Text] [Related] [New Search]